Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Reports"
DOI: 10.3892/or.2022.8277
Abstract: Chidamide, a selective histone deacetylase inhibitor, has antitumour effects. 5-azacitidine (5-AZA), a hypomethylating agent, is effective in treating acute myeloid leukaemia (AML) and myelodysplastic syndrome. However, to the best of our knowledge, the effect of… read more here.
Keywords: chidamide alone; chidamide; antitumour effects; acute myeloid ... See more keywords